Daewoong Pharmaceutical, established in 1945, is a leading South Korean pharmaceutical company with a 2023 revenue of KRW 1.22 trillion. The company invests heavily in research and development, evidenced by its 2023 R&D expenditure of KRW 145.3 billion. Daewoong is advancing a robust pipeline with innovations in areas like gastroesophageal reflux disease (GERD) and diabetes, focusing on novel drugs and biologics to address complex medical challenges​

VITVO : ion channel blocker discovery platform Long Acting Injectable DDS platform Microneedle DDS platform DW MSC : Stem cell development platform

Public

Pharma, Investor, CDMO, Bio